SCHEMBL6984518

SCHEMBL6984518

COc1ccc(N2CCN(C(=O)[C@H](CC(C)C)NC(=O)[C@H]3O[C@@H]3C(=O)O)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
CAPN1 P07384 6/20 0.48
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.45
MAPK1 P28482 4/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PKM P14618 1/20 0.45
AKR1C3 P42330 1/20 0.44
CAPN9 O14815 1/20 0.43
CTSB P07858 1/20 0.43
MEN1 O00255 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985559 0.89 CAPN1 (0.58) CAPN1ALDH1A1KDM4EGAAMAPK1
SCHEMBL6981297 0.88 CAPN1 (0.50) CAPN1ALDH1A1KDM4EKMT2AGAA
SCHEMBL6981138 0.88 CAPN1 (0.57) CAPN1ALDH1A1KDM4EKMT2ALMNA
SCHEMBL10619791 0.87 POLB (0.52) CAPN1ALDH1A1KDM4ELMNAMAPK1
SCHEMBL10853660 0.87 POLB (0.52) CAPN1ALDH1A1KDM4ELMNAMAPK1
SCHEMBL10615377 0.87 POLB (0.52) CAPN1ALDH1A1KDM4ELMNAMAPK1
SCHEMBL8212098 0.87 POLB (0.52) CAPN1ALDH1A1KDM4ELMNAMAPK1
SCHEMBL10853631 0.87 POLB (0.52) CAPN1ALDH1A1KDM4ELMNAMAPK1
SCHEMBL6985150 0.82 NPSR1 (0.50) CAPN1ALDH1A1KDM4EKMT2ALMNA
SCHEMBL6985309 0.80 CAPN1 (0.54) CAPN1ALDH1A1KDM4EKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed